TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Schwartz, L. H. AU - Litière, S. AU - Vries, E. PY - 2017 DA - 2017// TI - RECIST 11—update and clarification: from the RECIST committee JO - Eur J Cancer UR - https://doi.org/10.1016/j.ejca.2016.03.081.RECIST DO - 10.1016/j.ejca.2016.03.081.RECIST ID - Schwartz2017 ER - TY - JOUR AU - Darkeh, M. H. S. E. AU - Suzuki, C. AU - Torkzad, M. R. PY - 2009 DA - 2009// TI - The minimum number of target lesions that need to be measured to be representative of the total number of target lesions (according to RECIST) JO - Br J Radiol VL - 82 UR - https://doi.org/10.1259/bjr/72829563 DO - 10.1259/bjr/72829563 ID - Darkeh2009 ER - TY - JOUR AU - Muenzel, D. AU - Engels, H. P. AU - Bruegel, M. AU - Kehl, V. AU - Rummeny, E. J. AU - Metz, S. PY - 2012 DA - 2012// TI - Intra- and inter-observer variability in measurement of target lesions: Implication on response evaluation according to RECIST 1.1 JO - Radiol Oncol VL - 46 UR - https://doi.org/10.2478/v10019-012-0009-z DO - 10.2478/v10019-012-0009-z ID - Muenzel2012 ER - TY - JOUR AU - Tovoli, F. AU - Renzulli, M. AU - Negrini, G. PY - 2018 DA - 2018// TI - Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib JO - Eur Radiol VL - 28 UR - https://doi.org/10.1007/s00330-018-5393-3 DO - 10.1007/s00330-018-5393-3 ID - Tovoli2018 ER - TY - JOUR AU - Yoon, S. H. AU - Kim, K. W. AU - Goo, J. M. AU - Kim, D. -. W. AU - Hahn, S. PY - 2016 DA - 2016// TI - Observer variability in RECIST-based tumour burden measurements: a meta-analysis JO - Eur J Cancer VL - 53 UR - https://doi.org/10.1016/j.ejca.2015.10.014 DO - 10.1016/j.ejca.2015.10.014 ID - Yoon2016 ER - TY - STD TI - US Food and Drug Administration (2018) Clinical trial imaging endpoint process standards guidance for industry ID - ref7 ER - TY - JOUR AU - Skougaard, K. AU - McCullagh, M. J. D. AU - Nielsen, D. AU - Hendel, H. W. AU - Jensen, B. V. AU - Johannesen, H. H. PY - 2012 DA - 2012// TI - Observer variability in a phase II trial—assessing consistency in RECIST application JO - Acta Oncol VL - 51 UR - https://doi.org/10.3109/0284186X.2012.667149 DO - 10.3109/0284186X.2012.667149 ID - Skougaard2012 ER - TY - JOUR AU - Ford, R. AU - O’Neal, M. AU - Moskowitz, S. AU - Fraunberger, J. PY - 2016 DA - 2016// TI - Adjudication rates between readers in blinded independent central review of oncology studies JO - J Clin Trials VL - 6 UR - https://doi.org/10.4172/2167-0870.1000289 DO - 10.4172/2167-0870.1000289 ID - Ford2016 ER - TY - JOUR AU - Keil, S. AU - Barabasch, A. AU - Dirrichs, T. PY - 2014 DA - 2014// TI - Target lesion selection: an important factor causing variability of response classification in the Response Evaluation Criteria for Solid Tumors 1.1 JO - Invest Radiol VL - 49 UR - https://doi.org/10.1097/RLI.0000000000000048 DO - 10.1097/RLI.0000000000000048 ID - Keil2014 ER - TY - JOUR AU - Amoroso, V. AU - Pittiani, F. AU - Grisanti, S. PY - 2007 DA - 2007// TI - Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: Implications for response assessment with RECIST criteria JO - BMC Cancer VL - 7 UR - https://doi.org/10.1186/1471-2407-7-94 DO - 10.1186/1471-2407-7-94 ID - Amoroso2007 ER - TY - JOUR AU - Sargent, D. J. AU - Rubinstein, L. AU - Schwartz, L. PY - 2009 DA - 2009// TI - Validation of novel imaging methodologies for use as cancer clinical trial end-points JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.030 DO - 10.1016/j.ejca.2008.10.030 ID - Sargent2009 ER - TY - JOUR AU - Schwartz, L. H. AU - Bogaerts, J. AU - Ford, R. PY - 2009 DA - 2009// TI - Evaluation of lymph nodes with RECIST 1.1 JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.028 DO - 10.1016/j.ejca.2008.10.028 ID - Schwartz2009 ER - TY - JOUR AU - Tuma, R. S. PY - 2006 DA - 2006// TI - Sometimes size doesn’t matter: reevaluating RECIST and tumor response rate endpoints JO - J Natl Cancer Inst VL - 98 UR - https://doi.org/10.1093/jnci/djj403 DO - 10.1093/jnci/djj403 ID - Tuma2006 ER -